Cargando…

Palbociclib in breast cancer neoadjuvant setting

Cyclin-dependent kinase 4/6 inhibitors represent a major advance in breast cancer treatment, emerging as the standard of care of the initial treatment of hormone receptor-positive and HER2-negative metastatic breast cancer. Their activity in this subset of patients leads to interest in their use in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Duarte, Sílvia Alexandra Cabral, de Azevedo, Daniela Silva Pádua, Sarmento, Teresa Tomé Ribeiro Malheiro, Sousa, Marta Verónica Velho
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hospital Universitário da Universidade de São Paulo 2021
Materias:	Clinical Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8387079/ https://www.ncbi.nlm.nih.gov/pubmed/34458177 http://dx.doi.org/10.4322/acr.2021.309

Ejemplares similares

Neoadjuvant palbociclib on ER+ breast cancer (N007): clinical response and EndoPredict’s value
por: Chow, Louis W C, et al.
Publicado: (2017)

Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer
por: Gianni, Luca, et al.
Publicado: (2022)

Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer
por: Durairaj, Chandrasekar, et al.
Publicado: (2018)

A single institution experience with palbociclib toxicity requiring dose modifications
por: Gong, Jun, et al.
Publicado: (2017)

Basal cell carcinoma: multimodal treatment and the role of neoadjuvant vismodegib
por: Martins, Pedro Carvalho, et al.
Publicado: (2019)

Updates on managing advanced breast cancer with palbociclib combination therapy
por: McShane, Teresa M., et al.
Publicado: (2018)

Real‐world benefit of combination palbociclib and endocrine therapy for metastatic breast cancer and correlation with neutropenia
por: Sun, James, et al.
Publicado: (2021)

Two Novel Palbociclib-Resorcinol and Palbociclib-Orcinol Cocrystals with Enhanced Solubility and Dissolution Rate
por: Duan, Chenxin, et al.
Publicado: (2021)

Combination of palbociclib and radiotherapy for glioblastoma
por: Whittaker, Shane, et al.
Publicado: (2017)

Palbociclib-Induced Liver Failure
por: Atallah, Rami, et al.
Publicado: (2020)

AMPA Receptor Encephalitis in a Patient With Metastatic Breast Cancer Receiving Palbociclib: A Case Report
por: Matthews, Elizabeth, et al.
Publicado: (2022)

Profile of palbociclib in the treatment of metastatic breast cancer
por: Ehab, Moataz, et al.
Publicado: (2016)

Neoadjuvant endocrine therapy with or without palbociclib in low-risk patients: a phase III randomized double-blind SAFIA trial
por: Alsaleh, K., et al.
Publicado: (2023)

Regression of choroidal metastasis from breast carcinoma with palbociclib
por: Parakh, Shweta, et al.
Publicado: (2022)

Palbociclib in the treatment of recurrent ovarian cancer
por: Lee, Dai Wee, et al.
Publicado: (2020)

Palbociclib‐letrozole as first‐line treatment for advanced breast cancer: Updated results from a Japanese phase 2 study
por: Takahashi, Masato, et al.
Publicado: (2020)

Palbociclib Rechallenge for Hormone Receptor–Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial
por: Albanell, Joan, et al.
Publicado: (2023)

Neutropenia management with palbociclib in Japanese patients with advanced breast cancer
por: Masuda, Norikazu, et al.
Publicado: (2019)

Neutropenia due to palbociclib: A word of caution?
por: Pramanik, Raja, et al.
Publicado: (2016)

Palbociclib: COVID-19 infection: case report
Publicado: (2020)

Lysosomal trapping of palbociclib and its functional implications
por: Llanos, Susana, et al.
Publicado: (2019)

Palbociclib: Myelosuppression and gastrointestinal reactions: case report
Publicado: (2022)

Metronomic chemotherapy in the neoadjuvant setting: results of two parallel feasibility trials (TraQme and TAME) in patients with HER2+ and HER2− locally advanced breast cancer
por: Petry, V., et al.
Publicado: (2015)

De-escalation of axillary surgery in breast cancer patients treated in the neoadjuvant setting: a Dutch population-based study
por: Simons, J. M., et al.
Publicado: (2020)

Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer
por: Wilson, Florence R., et al.
Publicado: (2017)

The efficacy and safety of palbociclib combined with endocrine therapy in patients with hormone receptor-positive HER2-negative advanced breast cancer: a multi-center retrospective analysis
por: Zhang, Linhui, et al.
Publicado: (2021)

Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors
por: Buzatto, I.P.C., et al.
Publicado: (2017)

Modulation of thymidine phosphorylase by neoadjuvant chemotherapy in primary breast cancer
por: Toi, M, et al.
Publicado: (2004)

Small cell neuroendocrine carcinoma of the nasopharynx: a rare case report
por: Azevedo, Daniela, et al.
Publicado: (2017)

A phase II study of palbociclib plus letrozole plus trastuzumab as neoadjuvant treatment for clinical stages II and III ER+ HER2+ breast cancer (PALTAN)
por: Ademuyiwa, Foluso O., et al.
Publicado: (2023)

Palbociclib: an evidence-based review of its potential in the treatment of breast cancer
por: Cadoo, Karen A, et al.
Publicado: (2014)

Palbociclib in metastatic breast cancer: current evidence and real-life data
por: Serra, Francesco, et al.
Publicado: (2019)

Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication
por: Bellet, Meritxell, et al.
Publicado: (2019)

Pseudoprogression After Palbociclib with Aromatase Inhibitors Treatment in Metastatic Breast Cancer
por: Huang, Weiwei, et al.
Publicado: (2020)

Pharmacokinetic/Pharmacodynamic Model of Neutropenia in Real-Life Palbociclib-Treated Patients
por: Marouille, Alexandre Le, et al.
Publicado: (2021)

Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment
por: Ribeiro, J., et al.
Publicado: (2013)

Acquired palbociclib resistance in KRAS-mutant lung cancer
por: Sherr, Charles J.
Publicado: (2018)

Translating palbociclib to the clinic for DIPG - What is truly achievable?
por: Franshaw, Laura, et al.
Publicado: (2019)

Fatal Statin-Induced Rhabdomyolysis by Possible Interaction with Palbociclib
por: Nelson, Kellie Lynn, et al.
Publicado: (2017)

Early treatment-related neutropenia predicts response to palbociclib
por: McAndrew, Nicholas P., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7nqfl4j9i8n6ejiaf61l16be7g